CD31 antibody and other IHC marker antibodies: what each one labels
Marker antibodies fail in tissue for reasons that have nothing to do with the antibody: the wrong retrieval, a fixation time nobody recorded, a blocking step that leaves endogenous peroxidase active. This page works through three widely used markers, what each one is actually reporting, and the method variables that decide whether a section is interpretable.
- the two retrieval buffers worth testing on any new marker
- pH 6 / pH 9
- the containment human tissue sections are handled at
- BSL-2
- the authentication guidance a funded study is expected to follow
- NIH rigor
Figures in this panel are the method conventions and the biosafety and authentication guidance human tissue work is done under, named from the guidance itself and linked in the sources below. They are identifiers, not prices: BioBricks publishes verified prices for synthesis services only, and does not imply a reagent price index it has not measured.
- 4 vendor service pages verifiedevery figure matched verbatim to the vendor's page
- Quoted and dated, never estimatedlast verification pass 2026-08-24
- 1 service classes coveredeach with measured search demand behind it
Getting a marker stain to work
- Know what the marker labels, and what it does not. CD31 labels endothelium and is used to read vessel density, and it is also present on platelets and some leukocytes. GFAP labels astrocytes and rises with reactive change rather than with cell number. Iba1 labels microglia and macrophages and does not distinguish resident from infiltrating cells. Each of these caveats has been over-read in print.
- Fix the fixation before blaming the antibody. Formalin fixation time changes epitope availability substantially, and over-fixed archival material needs harder retrieval. Record fixation time with the block; a cohort fixed inconsistently cannot be compared however good the staining looks.
- Choose the retrieval condition empirically. Heat induced retrieval in citrate near pH six and in a Tris or EDTA buffer near pH nine give different results for the same antibody. Test both on a known positive section rather than following the first protocol you find.
- Block what actually causes the background. Endogenous peroxidase in blood-rich tissue, endogenous biotin in liver and kidney, and non-specific protein binding each need a different block. Adding more serum does not fix a peroxidase problem.
- Run the controls on the same slide run, every time. A known positive tissue, a negative tissue and a no-primary control. Where a section is scored quantitatively, the positive control also fixes the exposure and threshold, and without it two runs are not comparable.
Multiplexing three markers on one section
Raising the three primaries in different host species is the simplest route, because ordinary cross-adsorbed secondaries then separate them. Where two primaries share a host, sequential detection with an intervening blocking or stripping step is the alternative and it needs its own controls.
Choose fluorophores against the tissue's autofluorescence rather than against convenience. Brain and fixed archival tissue both fluoresce strongly in the green, which is where the brightest and cheapest conjugates sit.
Quantifying an image honestly
Fix the acquisition settings from the positive control and do not change them between sections. Auto-exposure across a cohort produces a dataset in which every section looks equally stained, which is the opposite of the measurement.
Decide the analysis before looking at the images: the region, the threshold rule and the unit. Thresholds chosen after seeing the result are the commonest source of an effect that will not replicate.
Buying an immunohistochemistry antibody
Prefer a clone with published images in your tissue and your fixation. For polyclonal reagents, buy a single lot for the whole cohort and record the lot with the data.
Recombinant monoclonals cost more and remove lot variation entirely. For a marker you will use across a multi-year study, that is usually the cheaper decision by the end.
Activation markers are not lineage markers
Some of the most used markers in tissue work do not identify a cell type at all: they identify a state. A protein expressed by fibroblasts only when those fibroblasts are activated appears in wound healing, in fibrosis and in tumour stroma alike, so the stain reports activation and the reader supplies the context.
Read as a lineage marker such a stain produces nonsense, and read as a state marker it is extremely informative. The safeguard is a second marker that does identify the lineage, on the same section, and a control tissue in which the state is absent.
An anti CD31 antibody labels more than endothelium
The standard endothelial marker used for vessel density is also present on platelets and on several leucocyte populations, so a count that treats every positive object as a vessel will overcount in inflamed or haemorrhagic tissue.
Where vessel density is the measurement, define the object rather than the pixel: a lumen, a minimum size, or a second endothelial marker to confirm. Stating the counting rule is what makes one laboratory's vessel density comparable with another's.
A dnmt1 antibody, and where the stain is read
A dnmt1 antibody stains a nuclear DNA methyltransferase, so the read is nuclear intensity against a graded control rather than a present or absent call, and the clone has to be shown not to cross react with DNMT3A or DNMT3B. Validation on a knockdown lysate is what separates a usable clone from one that stains a nucleus in every tissue.
A pr antibody and the scoring it belongs to
A pr antibody reports the progesterone receptor, and in breast pathology it is scored as a percentage of nuclei with an intensity, which means the antibody is only half the assay: fixation time, the retrieval buffer and the control block decide the number as much as the clone does. A clone with a published scoring cutoff is the one to use.
Common questions
- What does a cd31 antibody stain?
- Endothelial cells, which is why it is the usual marker for vessel density. It also marks platelets and subsets of leukocytes, so a count based on it should be restricted to structures that look like vessels.
- Does an anti GFAP antibody count astrocytes?
- Not reliably. It labels the intermediate filament, which is strongly upregulated in reactive astrocytes, so a stronger signal usually means more reactive cells rather than more cells. A nuclear marker is needed alongside it for counting.
- What is an iba1 antibody used for?
- Labelling microglia and macrophages, including their fine processes, which makes it the standard marker for microglial morphology. It does not separate resident microglia from infiltrating monocytes on its own.
- Which retrieval buffer should I start with?
- Try citrate near pH six and a Tris-EDTA buffer near pH nine on the same known positive tissue. Datasheet recommendations are a starting point and often reflect one laboratory's fixation rather than yours.
- Does a fibroblast activation protein antibody identify tumour fibroblasts?
- It identifies activated fibroblasts, which appear in wound healing and fibrosis as well as in tumour stroma. Pair it with a lineage marker on the same section and a control tissue in which the state is absent.
Get a shortlist for your project
Browse by service class
Sources
Cite or embed this figure
The median advertised gene synthesis price per base pair in the US research synthesis services market was $0.11 in August 2026, across 4 verified vendor service pages recorded in BioBricks Synthesis Price Index.
Cite as: "BioBricks Synthesis Price Index", updated 2026-08-24, https://biobricks.org/ihc-marker-antibodies/.